Navigation Links
ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
Date:12/2/2010

IRVINE, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in phytochemical reference standards and related contract analysis and research services, today announced that it has entered into a global agreement with Kappa Bioscience AS (Oslo, Norway) to supply analytical reference standards, quality control methods and related analytical testing services for Vitamin K2, Menaquinone-7(MK-7) in raw materials and finished goods.

"With increasing market demand for Vitamin K2 MK-7, there will be an increase in demand for reference standards, quality control methods, research tools and analytical services," said Frank Jaksch, CEO and co-founder of ChromaDex. "Since MK-7 is a vitamin product manufactured from different sources, it is critical that testing procedures are in place to ensure the quality and consistency of any MK-7 related ingredient or product."

Vitamin K2 is shown to have significant importance for optimal utilization of calcium in the body related to bone and cardiovascular health. Studies indicate that the Western diet is deficient in Vitamin K2. Thus, daily supplementation is expected to be beneficial for the bone building process as well as for cardiovascular health.

"The market needs a reliable and impartial third party expert like ChromaDex to bring clarity to Vitamin K analysis," said Egil Greve, CEO of Kappa Bioscience. "To date it has been difficult, if not impossible, to verify the label claims of Vitamin K2 in nutritional products. We expect that industry interest and confidence in Vitamin K2 will grow now that we can all confirm fortification," he added.  

About ChromaDexChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and
'/>"/>

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Majidi, M.D., a second-year resident in the Department ... of Medicine and Health Sciences, received at $154K ... the presence of diffuse brain swelling and injury ... to epidemiological studies, intracerebral hemorrhage accounts for less ... the least treatable form of stroke, with the ...
(Date:9/19/2014)... BCC Research reveals in its new ... , the global market for human antifungal therapeutics is ... with a five-year compound annual growth rate (CAGR) of ... a steady 3.8% CAGR. , Given the current world ... with the incidence of increasing mortality and the severity ...
(Date:9/19/2014)... Dallas, Texas (PRWEB) September 19, 2014 ... blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 ... released from a variety of cells, including mast cells ... CysLT receptors. Several studies have determined that there are ... of asthmatics compared with non-asthmatic individuals. The production of ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... agents, an integral part of the medical imaging market, ... organs. Effervescent technology developments over the past three decades ... medical diagnostics. From barium and iodine based agents used ... as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Aug. 13 As reported in publications and news,outlets ... "buck" teeth was replaced at the summer games opening ... the decision spawned,disbelief around the globe, sadly, the phenomenon ... of their teeth is nothing new., In a ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... 3 new reports raise question of how long a heart ... 13 (HealthDay News) -- Three new reports challenge current guidelines ... taking a heart from an infant organ donor. , There,s ... no question that there aren,t enough donor organs to save ...
... Weiner Says Calls for,Privatization and ,Reform, are Granny-on-Your-Own, ... WASHINGTON, Aug. 13 On Social Security,s,73rd Anniversary ... of Staff,Robert Weiner is saying, "Calls to ,reform, ... Street,giveaway which would turn Social Security from a ...
... Held Thursday, August 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "Alseres made solid ...
... -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... Republic of China,("PRC"), today announced that it will ... on Monday, August 18, 2008 to discuss results ... Dr. Zhongyi Liu, Chairman and Chief Executive Officer ...
Cached Medicine News:Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Infant Heart Transplant Controversy Continues 2Health News:Infant Heart Transplant Controversy Continues 3Health News:Infant Heart Transplant Controversy Continues 4Health News:Social Security's 73rd Anniversary 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: